In this study, we compared CDK9 protein expression in matched samples of Barrett's esophagus and invasive carcinoma from patients with esophageal adenocarcinoma and assessed in vitro and in vivo effects of genetic downregulation (shCDK9) and pharmaceutical inhibition of CDK9. Here, CDK9 is linked to invasive carcinoma.